anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a preparation which is used for rapidly preventing and treating all cardiovascular and cerebrovascular diseases, such as cerebral thrombus, stroke, paralysis, and so on. In particular, fruits and vegetables are used as raw materials, and the preparation and drop of vegetable enzyme soup are scientifically extracted to prepare the preparation. The enzyme of the preparation of ''vegetable enzyme soup'' can decompose ''nitrosourea ammonia'' of cancer; the 'indol' can inhibit and kill cancer cells; thus the preparation can achieve the purposes of rapidly preventing cancer, curing cancer, and preventing and treating stroke and paralysis. The preparation has 100 percent of restoration state for patients suffering from of various types of cancer and cancer of the later period. For the patient of the late period who has been rescued by oxygen, 200 milliliters of ''vegetable enzyme soup'' and 200 milliliters of tea of brown rice are alternatively transmitted into the stomach of the patient by a catheter in 45 minutes, so that the patient can revive and be gradually cured. Moreover the preparation can stop the activities of all types of cancer in 3 days, and can be used for curing the patient about in 3 months to restore the physical functions. The enzyme can rapidly dissolve and dispel the blood dirt of lipid, plaque and thrombus on the vessel wall of a human body, so as to completely clean and dredge capillary vessels; the blood vessel has flexibility and the blood can flow smoothly. Therefore, the preparation can fundamentally stop and prevent all cardiovascular and cerebrovascular diseases, such as coronary heart diseases, myocardial infarction, vascular sclerosis, cerebral haemorrhage, cerebral thrombus, stroke, paralysis, and so on.
PURPOSE:To obtain the titled remedy by filling a liquefied gas in a spraying container under a specific pressure. When the agent is sprayed toward the diseased part, the surface skin of the part is peeled off immediately after feeling refreshing feeling and a certain extent of pain and the disease can be cured completely without further medical treatment. CONSTITUTION:A gas liquefied under a pressure of 2-20atm, preferably 4-8atm is filled in a container capable of spraying the gas. The liquefied gas is a composition composed mainly of butane and containing extremely small amount of impurities consisting of hydrocarbons having similar carbon number, such as propane, ethane, pentane, etc. It is applied, for example, by cleaning the foot, wiping off the moisture from the skin, sterilizing the diseased part with 'Oxyfull(R)', and spraying the liquefied gas using a sprayer filled with the liquefied gas, e.g. with a cigarette lighter. The treatment is repeated thrice a day and continued for 1 week. The surface skin of the diseased part is peeled off, and the athlete's foot is cured completely without causing the relapse of the disease.
PROBLEM TO BE SOLVED: To obtain the subject medicine that can prevent tizanidin hydrochloride used for treatment of tension pain, cerebral and spinal contractual diseases, from yellowing by using tizanidin hydrochloride and a specific excipient in combination in the preparation. SOLUTION: Tizanidin hydrochloride is used in combination with an excipient that can prevent tizanidin hydrochloride from yellowing to prepare the subject medicine of non-yellowing centrally acting muscle relaxant. As a yellowing- preventive excipient, the preparation includes a yellowing-preventive binder and the preferred binder is a polysaccharide, for example, gum Arabic or pullulan. The weight ratio of tizanidin and the excipient is selected depending on the form of the preparations and usually 0.01-10 wt.%. The forms of the preparation are, for example, tablets, capsules, dry syrup, granules, powder or injection solution. The dose of tizanidin as a active ingredient is about 3-9 mg/day.
Introduction: Surgical treatment of obesity in patients over 65 years of age is controversial. For patients in this age group, there is a prevailing concept that the risk / benefit ratio of the procedure should be evaluated for each individual patient, without determining objective criteria or outcomes that characterize this benefit. Increased surgical risk in patients older than 65 years is undoubtedly a limiting factor for the broader indication of bariatric surgery in this population. The two most applied surgical techniques are Sleeve Gastrectomy and Roux-en-Y Gastric Bypass. Most of the studies that evaluated the two techniques in elderly patients are retrospective, prospective non-randomized, or contemplated only one technique. Recent, studies concluded that in the elderly the weight loss with Gastric Bypass was higher, but the surgical morbidity with the Sleeve was lower and there was no difference in the resolution of comorbidities between the two techniques. In evaluating the benefits of surgery, most studies address outcomes such as weight loss and control of metabolic and cardiovascular comorbidities. Outcomes that are specific to the treatment of obesity in the elderly, such as improvement of functionality, decreased fragility and improvement of the quality of life have not been studied yet. In this field, there is concern that excessive weight loss, accompanied by loss of muscle mass may compromise the mentioned parameters, especially in individuals who already have loss of bone and muscle mass before surgery. For this reason, the assessment of bone mass and body composition in the preoperative period of these individuals is fundamental. In order to identify the benefits of weight loss promoted by surgery and life expectancy, the elderly patients in preparation for operation at the Bariatric Surgery Unit of the Hospital das Clinicas University of São Paulo School of Medicine are submitted to a geriatric evaluation, which includes the analysis of their functional dependency profile, Important prognostic factor in this population. Objectives: The primary objective of the study will be to evaluate surgical morbidity and short-term (weight loss, comorbid control) outcomes of surgical treatment of obesity in patients over 65 years of age, comparing two techniques: Sleeve Gastrectomy (SG) and Gastric Bypass (GB). The secondary objective will be to evaluate the body composition of the individuals, before and after the surgery, comparing the two techniques. Patients and methods: This is a prospective study, in which 40 consecutive patients, aged 65 years and over, will be admitted to the Bariatric and Metabolic Surgery Unit of the Discipline of Digestive System Surgery of Hospital das Clinicas University of São Paulo School of Medicine with indication criteria for bariatric surgery. Patients will be randomized into two groups according to the surgical technique to be used: SG or GB. Data related to surgical morbidity, weight loss, control of comorbidities, nutritional deficiencies, changes in body composition and functionality will be evaluated and compared after a follow-up of at least 12 months.
The invention discloses a flupirtine maleate sustained release tablet. The flupirtine maleate sustained release tablet is prepared from, by weight, 0.2 parts of flupirtine maleate, 70 to 190 parts of a sustained-release matrix material, and 10 to 20 parts of a lubricant. A preparation method of the flupirtine maleate sustained release tablet comprises following steps: material preparation, total blending, granulating, total blending, performing, and aluminum plastic packaging. The flupirtine maleate sustained release tablet is capable of relieving pain, relaxing muscle, and protecting nerve. According to the preparation method, novel sustained release preparations are adopted. According to the sustained release preparations, medicine releasing rate of medicines from the preparations is slowed, and absorption rate of the medicines in body is reduced, so that more stable treatment effects are achieved. Compared with oral liquid, the flupirtine maleate sustained release tablet is high in drug stability, and is convenient for packaging, transportation, and storing; and the preparation method is simple and convenient, and is suitable for industrial production.
The invention relates to medlar tea and its production method. The tea is composed of medlar leaves, medlar root, fructus lycii, and medlar flower at a wt. ratio of 1:0.1-0.4:0.07-0.27:0.03-0.15. The medlar leaves is medlar leaves tea prepared by fresh medlar leaves through traditional tea process. The medlar flower is fresh medlar flower dried in the shade. Fructus lycii contains low carbohydrates. Medlar root is dried root bark with duramen removed. The invention contains the essence of leaves, flowers, fruits and roots of medlar. The method of the invention combines modern scientific technology and traditional technique, and produces an easy, nutritional health cultivation drink with high active component extraction ratio and special function. The tea is emerald green, tasty, fragrant, can remove heat to loosen bowels, moisten lung, improve eyesight, and calm the nerves.
Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
BACKGROUND: Harsh temperature exposure has been associated with a high risk of cardiovascular events. We sought to investigate the influence of temperature change on long-term incidence of acute myocardial infarction (AMI) in Korean patients.
METHODS: From the National Health Insurance Service (NHIS) customized health information database (from 2005 to 2014), data from a total of 192,567 AMI patients was assessed according to the International Classification of Disease 10th edition code and matched with temperature reports obtained from the Korea Meteorological Administration database. We analyzed data for a 10-year period on a monthly and seasonal basis.
RESULTS: The incidence rate per 100,000 year of AMI exhibited a downward trend from 69.1 to 56.1 over the period 2005 to 2014 (P < 0.005), and the seasonal AMI incidence rate per 100,000 year was highest in spring (63.1), and winter (61.3) followed by autumn (59.5) and summer (57.1). On a monthly basis, the AMI incidence rate per 100,000 year was highest during March (64.4) and December (63.9). The highest incidence of AMI occurred during temperature differences of 8-10° in each season. Moreover, AMI incidence tended to increase as the mean temperature decreased (r = -0.233, P = 0.001), and when the mean daily temperature difference increased (r = 0.353, P < 0.001).
CONCLUSION: The AMI incidence rate per 100,000 year has a decreasing trend over the 10-year period, derived from the Korean NHIS database. Modest daily temperature differences (8-10°) and the spring season are related to higher AMI incidence, indicating that daily temperature variation is more important than the mean daily temperature.
Alpha-tubulin 4A encoding gene (TUBA4A) has been associated with familial amyotrophic lateral sclerosis and frontotemporal dementia, based on identification of likely pathogenic variants in patients from distinct amyotrophic lateral sclerosis and frontotemporal dementia cohorts. By screening a multicentric French cohort of 448 unrelated probands presenting with cerebellar ataxia, we identified ultra-rare TUBA4A missense variants, all being absent from public databases and predicted pathogenic by multiple in silico tools. In addition, gene burden analyses in the 100 000 Genomes project (100KGP) showed enrichment of TUBA4A rare variants in the inherited ataxia group compared to controls [odds ratio: 57.0847 (10.2-576.7); P = 4.02 ×10-7]. Taken together, we report 12 patients presenting with spasticity and/or cerebellar ataxia and harbouring a predicted pathogenic TUBA4A missense mutation, including five confirmed de novo cases and a mutation previously reported in a large family presenting with spastic ataxia. Cultured fibroblasts from three patients harbouring distinct TUBA4A missense showed significant alterations in microtubule organization and dynamics, providing insight of TUBA4A variants pathogenicity. Our data confirm the identification of a hereditary spastic ataxia disease gene with variable age of onset, expanding the clinical spectrum of TUBA4A associated phenotypes.
Adolescents attending a public university that belongs to the same "health area" with similar population characteristics in each province. The inclusion criteria will be students enrolled in different undergraduate studies in a public University (18-23 years old), who don´t need curricular adaptation. We will exclude health science studies because we suppose that they are students who may have worked more on compassionate awareness.
PURPOSE:To obtain the subject suppressant, containing a serrapeptase, having accelerated fibrinolytic activities and vascular-permeable suppressing actions and useful as a therapeutic and preventing agent for a burn, cancer, sepsis, leukemia, etc., due to hot water, fire, ultraviolet rays, etc. CONSTITUTION:This suppressant contains a serrapeptase obtained by culturing a microorganism, belonging to the genus Serratia and having the ability to produce the serrapeptase, e.g. Serratia sp. E15 strain in a culture medium, etc. Furthermore, the content of the serrapeptase in the suppressant is preferably 1-50wt.%, especially 1-30wt.%. The daily dose of the suppressant for an adult is usually 10-5000mug/kg body weight, preferably 100-1000mug/kg body weight expressed in terms of the amount of the serrapeptase.
Appetite stimulants are the common treatment for cancer-induced anorexia. However, only 30% of advanced cancer patients respond and benefit from appetite stimulants, which may be due in part to sensory abnormalities, as a person who is experiencing food aversion due to taste and smell changes may be unable to respond to these agents. Of the appetite stimulants available for use in clinical practice only Marinol, or THC, has the potential to increase food intake by improving appetite as well as by amplifying the taste of food through the brain's reward pathway.

A 22-day, double blind, randomized, placebo-controlled trial will be conducted. Participants will start at 2.5mg of THC or placebo once daily for the first 3 days and then increase to 2.5mg of THC or placebo twice daily before lunch and supper. Participant's will complete the following survey tools pre and post-treatment: Taste and Smell Survey to assess the severity and change in chemosensory complaint scores; 3-day dietary record to determine the change in caloric intake and shift in food preference by macronutrient analysis; 24-hour urine collections to validate the 3-day dietary record; Satiety Labelled Intensity Magnitude scale for subjective appetite ratings; Food Preference Checklist to assess objective shifts in macronutrient and flavor preferences; Functional Assessment of Anorexia/Cachexia Therapy questionnaire to assess participant's QOL; interview to determine the cause and effects of chemosensory alterations; Edmonton Symptom Assessment Scale to assess nausea; and Side Effect Survey to document the tolerability of the drug (post-treatment only). Participants will complete the survey tools with the aid of the researcher. All tools are short and easy to complete, which minimizes patient burden.
The devices, methods, and compositions disclosed herein accomplish robust cell encapsulation in polymer microparticles using a vertically oriented microfluidic device. A hydrophilic polymer precursor solution is flowed into a first inlet channel, which extends inward from an upper surface of the device housing. A hydrophobic fluid is flowed into a second inlet channel, which extends inward from a lower surface of the device housing. The two inlet channels meet at a junction, and an outlet channel extends away from the two inlet channels. When the two inwardly flowing streams meet at the junction, the polymer precursor solution disperses into the hydrophobic fluid. The dispersed precursor droplets are photopolymerized into microparticles as they travel through the outlet channel. The resulting microparticles are highly uniform, and are larger than conventionally formed microparticles. Cells of varying types can be encapsulated with high viability and spatial uniformity.
<P>PROBLEM TO BE SOLVED: To solve the problem of current emulsifiers for foods, including synthetic additives e.g. glycerol fatty acid esters, derivatives of the glycerol esters and sucrose fatty acid esters, and natural additives, e.g. lecithin, and emulsifiers for foods and drinks having high emulsifying action, e.g. the natural product originated gum arabic, soy bean polysaccharide and proteins, that such a natural product originated emulsifiers are commonly inferior to synthetic additive emulsifiers in emulsifying action and also have problems associated with the flavor, resulting in common use of synthetic additives in foods and drinks, in order to provide natural product originated emulsifiers having high emulsifying action and foods and drinks obtained with the emulsifiers.  <P>SOLUTION: An emulsifier composition contains the extract of sesame. The extract is preferably the water extract. Foods and drinks and cosmetics containing the composition are also provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Chronic kidney disease mineral bone disorder (CKD-MBD) is a complex clinical syndrome responsible for the accelerated cardiovascular mortality seen in individuals afflicted with CKD. Current approaches to therapy have failed to improve clinical outcomes adequately, likely due to targeting surrogate biochemical parameters as articulated by the guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO). We hypothesized that using a Systems Biology Approach combining machine learning with mathematical modeling, we could test a novel approach to therapy targeting the abnormal movement of mineral out of bone and into soft tissue that is characteristic of CKD-MBD. The mathematical model describes the movement of calcium and phosphate between body compartments in response to standard therapeutic agents. The machine-learning technique we applied is reinforcement learning (RL). We compared calcium, phosphate, parathyroid hormone (PTH), and mineral movement out of bone and into soft tissue under four scenarios: standard approach (KDIGO), achievement of KDIGO guidelines using RL (RLKDIGO), targeting abnormal mineral flux (RLFLUX), and combining achievement of KDIGO guidelines with minimization of abnormal mineral flux (RLKDIGOFLUX). We demonstrate through simulations that explicitly targeting abnormal mineral flux significantly decreases abnormal mineral movement compared with standard approach while achieving acceptable biochemical outcomes. These investigations highlight the limitations of current therapeutic targets, primarily secondary hyperparathyroidism, and emphasize the central role of deranged phosphate homeostasis in the genesis of the CKD-MBD syndrome.NEW & NOTEWORTHY Artificial intelligence is a powerful tool for exploration of complex processes but application to clinical syndromes is challenging. Using a mathematical model describing the movement of calcium and phosphate between body compartments combined with machine learning, we show the feasibility of testing alternative goals of therapy for Chronic Kidney Disease Mineral Bone Disorder while maintaining acceptable biochemical outcomes. These simulations demonstrate the potential for using this platform to generate and test hypotheses in silico rapidly, inexpensively, and safely.
<P>PROBLEM TO BE SOLVED: To provide a CD8T cell activation-inhibiting agent, and a therapeutic agent for rheumatism and a DNA vaccine for treating rheumatism.  <P>SOLUTION: The CD8T cell activation-inhibiting agent comprises a Jagged 1 gene or a Jagged 1 protein. The CD8T cell activation-inhibiting agent inhibits activation of a CD8T cell and accordingly makes prevention or treatment of rheumatism possible. Preferably, the gene above is particularly a structural gene in an extracellular region of the Jagged 1 protein. Preferably, a recombinant vector having the structural gene inserted therein is used as the DNA vaccine.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE:To obtain the subject hardening agent for treating lesion of digestive organ containing an inorganic acid or organic acid and its salt, a water-soluble zinc compound, an alcohol and water, being stable, not causing precipitation, insoluble foreign matter and coloring and having clear appearance. CONSTITUTION:(A) An inorganic acid (e.g. sulfuric acid) or an organic acid (e.g. citric acid) and its salt are blended with (B) a water-soluble zinc compound (e.g. zinc sulfate), (C) an alcohol (e.g. benzyl alcohol) and (D) water and further, as necessary, (E) an antioxidant (e.g. sodium hydrogen sulfite), (F) an antiseptic and analgesic agent (e.g. tannin) and (G) polysaccharides which are auxiliary components for enhancing viscosity of the preparation (e.g. dextran) are added to the blend to provide the objective uniform and clear hardening agent for treating lesion of digestive organ such as hemorrhoid, polyp of colon, prolapse of rectal mucous membrane, proctocele, rectal ulcer or hepatic tumor and being stable and not causing precipitation, formation of insoluble foreign matters and coloring even if it is stored for a long period.
Chrononutrition is a branch of chronobiology that evaluates nutrients and the pathways implicated in their regulation in accordance with circadian rhythms. Sleep deprivation and disturbances have been strongly associated with the progression of different metabolic alterations, and the time of food intake plays a fundamental role in maintaining metabolic homeostasis. It has been demonstrated that not only the components of food are important, but quantity and quality are also crucial elements of a healthy eating pattern. Chrononutrition is an emerging tool that could help improve dietary interventions beyond those derived from consuming an adequate amount of each nutrient. Diabetes is a complex endocrine pathology characterized by sustained hyperglycemia. Dietary changes are a key component in obtaining adequate control and preventing long-term complications. Recent studies emphasize the use of chrononutrition and its components as a novel dietary intervention that could improve metabolic control. The use of chrononutrition as a dietary intervention is faced with challenges such as the presence of gaps in the literature that limit its implementation. This emphasizes the imperative need for additional research that can lead to an evidence-based use of this intervention.
Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
The present invention provides conjugated double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and/or sugar modified nucleosides. More particularly, the present compositions comprise a linked conjugate group on one strand and a non hybridizing region of 2′-modified nucleosides on the other strand. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.